Intra‑articular Hyaluronic Acid for Severe Knee Osteoarthritis – Guideline Summary

Guideline Stance

The American Academy of Orthopaedic Surgeons (AAOS) 2022 guideline states that intra‑articular hyaluronic acid (HA) is not consistently supported by 17 high‑quality and 11 moderate‑quality studies; the calculated number‑needed‑to‑treat is 17, and no patient subgroup has been identified that reliably benefits from HA. (Strong recommendation against use based on high‑quality evidence) 1
The American College of Rheumatology/Arthritis Foundation (ACR/AF) 2020 guideline conditionally recommends against intra‑articular HA for knee OA, noting that when only low‑risk‑of‑bias trials are considered, the effect size versus saline approaches zero. (Conditional recommendation, low certainty) 2

Observational data show that patients with advanced (severe) knee OA experience worse clinical response to HA injections compared with those with milder disease; a retrospective study found structural severity negatively correlated with treatment benefit. (Low‑certainty observational evidence) 1, 3
Most randomized HA trials exclude patients with severe OA, limiting the applicability of positive findings to this subgroup. (Evidence gap) 3, 4
Studies of platelet‑rich plasma, which share a similar injection regimen, demonstrate poorer outcomes in severe knee OA, suggesting a comparable pattern for HA. (Indirect low‑certainty evidence) 1

Meta‑analyses that include poor‑quality trials report pooled effect sizes approximately twice as large as those derived from higher‑quality trials, indicating inflation of benefit by methodological flaws. (Moderate‑certainty evidence of bias) 5, 6, 7
Publication bias and unclear clinical significance have been identified as contributors to the apparent positive results of HA in earlier literature. (Moderate‑certainty evidence of bias) 5, 6
When analyses are restricted to low‑risk‑of‑bias studies, the HA effect size approaches zero, aligning with the ACR/AF conditional recommendation. (High‑certainty evidence due to limited data) 2

Intra‑articular corticosteroid injections provide short‑term pain relief lasting 1 week to 3 months and produce clinically important improvements. (Moderate‑certainty evidence) 1, 5, 7
Oral non‑steroidal anti‑inflammatory drugs (NSAIDs) consistently improve pain and functional scores in knee OA. (Moderate‑certainty evidence) 1
Weight‑loss programs and structured exercise are recommended to reduce joint load and improve symptoms when applicable. (Low‑certainty evidence, widely accepted) 1
Total knee arthroplasty should be considered for patients with radiographic evidence of severe knee OA who have refractory pain and functional limitation despite conservative measures. (Strong recommendation based on surgical outcome data) 8, 3

Do not rely on older meta‑analyses that incorporated low‑quality HA trials when making treatment decisions. (Guideline caution) 2
Do not expect HA to delay the need for joint replacement; evidence for disease‑modifying effects is minimal. (Guideline caution) 4, 8
Do not assume HA will be as effective in severe OA as it may be in mild‑to‑moderate disease; response is markedly poorer in advanced stages. (Guideline caution) 3
Recognize that the typical 3‑5 weekly injection schedule imposes logistical and cost burdens without proven benefit in severe OA. (Guideline caution) 4, 8